Effect of antiadhesion molecule mAb on PMN interaction with HUVECs under flow
Treatment . | Total interactions, no. per field . | PMN rolling, no. per field . | PMN adhesion, no. per field . |
|---|---|---|---|
| None | 287 ± 67 | 238 ± 60 | 49 ± 7 |
| Anti–l-selectin mAb | 82 ± 30* | 47 ± 19* | 35 ± 11 |
| Anti-PSGL-1 mAb | 127 ± 26* | 59 ± 4* | 68 ± 22 |
| Peptide Ac2-26 | 119 ± 50* | 65 ± 32* | 54 ± 18 |
Treatment . | Total interactions, no. per field . | PMN rolling, no. per field . | PMN adhesion, no. per field . |
|---|---|---|---|
| None | 287 ± 67 | 238 ± 60 | 49 ± 7 |
| Anti–l-selectin mAb | 82 ± 30* | 47 ± 19* | 35 ± 11 |
| Anti-PSGL-1 mAb | 127 ± 26* | 59 ± 4* | 68 ± 22 |
| Peptide Ac2-26 | 119 ± 50* | 65 ± 32* | 54 ± 18 |
Human PMNs were incubated with 30 μM peptide Ac2-26, 20 μg/mL anti–l-selectin mAb, or 10 μg/mL anti-PSGL-1 mAb for 10 minutes prior to flow over TNF-α-stimulated (10 ng/mL, 4 hours) HUVECs. The numbers of total PMN-endothelial interactions and rolling and adherent PMNs were quantified off-line as described in “Materials and methods.” Data are presented as mean ± SEM of 3 independent experiments.
P < .05 versus no treatment group